Drug Resistance

HIV Drug Resistance Assay Available For Clinical Management

Published in Blood Weekly, April 14th, 1997

The "future of antiretroviral therapy" has arrived ahead of schedule.

A new blood test permits physicians to rapidly determine whether a patient's HIV strain is susceptible to particular anti-HIV drugs. The genotypic assay, dubbed HIV-1 GenotypR Plus, is manufactured by Specialty Laboratories Inc., Santa Monica, California.

It has been less than three months since a leading AIDS researcher expressed the hope that such a test would be available by the end of the decade.

"I think the future of antiretroviral therapy will certainly be improved with a phenotypic or genotypic assay," University of California, San Diego researcher...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry